Atrial Fibrillation
Monday, October 21st, 2013
Journal of General Internal Medicine: October 2013 The decision as to whether to use more expensive novel oral anticoagulants (NOACs) or invest resources for quality improvement of warfarin therapy requires input from both clinical and economic analyses. OBJECTIVE Cost-effectiveness of NOACs compared to warfarin therapy at various levels of patient-time in therapeutic range (TTR) in patients […]
Atrial Fibrillation
Monday, October 21st, 2013
CIRCEP: October 10, 2013 Background—Pulmonary vein antrum isolation (PVAI) in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF) has been reported to have satisfactory results at the mid and short-term follow-up. We determined the outcomes at the long-term follow-up of PVAI in these patients. Methods and Results—We enrolled 43 patients with HCM and AF (28% […]
Atrial Fibrillation
Monday, October 21st, 2013
Circulation: Arrhythmia and Electrophysiology: 10/1/13 Bachmann’s bundle (BB), also known as the interatrial bundle, is well recognized as a muscular bundle comprising of parallel aligned myocardial strands connecting the right and left atrial walls and is considered to be the main pathway of interatrial conduction.1 Disruption of the bundle’s structure causes interatrial conduction block (IAB),2 which is associated […]
Atrial Fibrillation
Monday, October 21st, 2013
Arteriosclerosis, Thrombosis, and Vascular Biology: September 12, 2013 Objective—Atrial fibrillation (AF) and atherosclerotic vascular disease are closely entangled disorders and often coexist. Whether atherosclerosis predisposes to the development of AF has not been fully elucidated. Approach and Results—This study was performed within the framework of the Bruneck Study, a population-based survey with near-complete participation (932 of […]
Atrial Fibrillation
Monday, October 21st, 2013
Circulation: Arrhythmia and Electrophysiology: August 31, 2013 Background—Few clinical indices identify the propensity of patients to atrial fibrillation (AF) when not in AF. Repolarization alternans has been shown to indicate AF vulnerability, but is limited in its sensitivity to detect changes in action potential (AP) duration (APD), which may be subtle. We hypothesized that spectral analysis […]
Clinical Trials
Monday, October 21st, 2013
STROKEAHA: October 17, 2013 Background and Purpose—Early vascular events are an important cause of morbidity and mortality in the first 3 months after a stroke. We aimed to investigate the effects of MLC601 on the occurrence of early vascular events within 3 months of stroke onset. Methods—Post hoc analysis was performed on data from subjects included […]
Clinical Trials
Monday, October 21st, 2013
STROKEAHA: October 17, 2013 Background and Purpose—A high rate of postprocedure complications in the Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial has raised concerns whether such results are representative of intracranial stent placement in actual routine practice. Methods—Using the Nationwide Inpatient Sample from 2008 to 2010, patients with cerebral ischemic events treated […]
Clinical Trials
Monday, October 21st, 2013
Eur Heart J: October 15, 2013 Aims We investigated the prevalence of prior myocardial infarction (MI) and incidence of ischaemic cardiovascular (CV) events among atrial fibrillation (AF) patients. Methods and results In ROCKET AF, 14 264 patients with nonvalvular AF were randomized to rivaroxaban or warfarin. The key efficacy outcome for these analyses was CV death, MI, and […]
Clinical Trials
Monday, October 21st, 2013
STROKEAHA: October 10, 2013 Background and Purpose—Hallmarks of vulnerable atherosclerotic plaques are inflammation that can be assessed with 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography, and increased neovascularization that can be evaluated by dynamic contrast–enhanced-MRI. It remains unclear whether these parameters are correlated or represent independent imaging parameters. This study determines whether there is a correlation between inflammation and […]
Clinical Trials
Monday, October 21st, 2013
JACC: October 2013 Objectives Analyze the impact of dabigatran plasma concentrations, patient demographics and ASA use on frequencies of ischemic strokes/systemic emboli and major bleeds in atrial fibrillation patients . Background The efficacy and safety of dabigatran etexilate were demonstrated in the RE-LY trial, but a therapeutic concentration range has not been defined. Methods In a prespecified analysis […]
